Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 20/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gsk-729327 SCHEMBL3250063 | 1.00 | GRIA2 (1.00) | GRIA2CYP1A2CYP2C19 | |
| Gsk-729327 SCHEMBL3245255 | 1.00 | GRIA2 (1.00) | GRIA2CYP1A2CYP2C19 | |
| SCHEMBL3256854 | 0.87 | GRIA2 (1.00) | GRIA2CYP1A2CYP2C19 | |
| SCHEMBL3248290 | 0.87 | GRIA2 (1.00) | GRIA2CYP1A2CYP2C19 | |
| SCHEMBL3245260 | 0.86 | GRIA2 (0.77) | GRIA2CYP1A2CYP2C19 | |
| SCHEMBL3251780 | 0.85 | GRIA2 (0.74) | GRIA2CYP1A2CYP2C19 | |
| Gsk-729327 SCHEMBL5174888 | 0.84 | GRIA2 (0.76) | GRIA2CYP1A2CYP2C19 | |
| SCHEMBL3248286 | 0.84 | GRIA2 (0.73) | GRIA2CYP1A2CYP2C19 | |
| SCHEMBL3247774 | 0.83 | GRIA2 (0.72) | GRIA2CYP1A2CYP2C19 | |
| SCHEMBL3253572 | 0.82 | GRIA2 (1.00) | GRIA2CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572819-B2 | Compounds which potentiate glutamate receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2009-08-11 | — | — | US | claimed |
| US-20080194648-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED | 2008-08-14 | — | — | US | claimed |
| US-20070161638-A1 | Compounds which potentiate glutamate receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2007-07-12 | — | — | US | claimed |
| EP-1944289-B1 | Compounds which potentiate glutamate receptor and uses thereof in medicine | GLAXO GROUP LTD (GB) | 2010-05-19 | — | — | EP | disclosed |
| EP-1944289-B1 | Compounds which potentiate glutamate receptor and uses thereof in medicine | GLAXO GROUP LTD (GB) | 2010-05-19 | — | — | EP | disclosed |
| US-7618969-B2 | Compounds which potentiate glutamate receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2009-11-17 | — | — | US | disclosed |
| US-7618969-B2 | Compounds which potentiate glutamate receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2009-11-17 | — | — | US | disclosed |
| US-7618969-B2 | Compounds which potentiate glutamate receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2009-11-17 | — | — | US | disclosed |
| US-7572819-B2 | Compounds which potentiate glutamate receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2009-08-11 | — | — | US | disclosed |
| US-7572819-B2 | Compounds which potentiate glutamate receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2009-08-11 | — | — | US | disclosed |
| US-7572819-B2 | Compounds which potentiate glutamate receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2009-08-11 | — | — | US | disclosed |
| US-20080194648-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED | 2008-08-14 | — | — | US | disclosed |
| US-20080194648-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED | 2008-08-14 | — | — | US | disclosed |
| EP-1944289-A1 | Compounds which potentiate glutamate receptor and uses thereof in medicine | Glaxo Group Limited (GB) | 2008-07-16 | — | — | EP | disclosed |
| EP-1944289-A1 | Compounds which potentiate glutamate receptor and uses thereof in medicine | Glaxo Group Limited (GB) | 2008-07-16 | — | — | EP | disclosed |
| US-20080139472-A1 | UPREGULATING BDNF LEVELS TO MITIGATE MENTAL RETARDATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-06-12 | — | — | US | disclosed |
| US-20070161638-A1 | Compounds which potentiate glutamate receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2007-07-12 | — | — | US | disclosed |
| US-20070161638-A1 | Compounds which potentiate glutamate receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2007-07-12 | — | — | US | disclosed |
| US-20070161638-A1 | Compounds which potentiate glutamate receptor and uses thereof in medicine | GLAXO GROUP LIMITED (GB) | 2007-07-12 | — | — | US | disclosed |
| WO-2006015828-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161638-A1 | Compounds which potentiate glutamate receptor and uses thereof in medicine | GRM1, GRIN1, HCAR1 | GRIA2 39/4885CYP1A2 980/4885CYP2C19 904/4885 |
| US-20080139472-A1 | UPREGULATING BDNF LEVELS TO MITIGATE MENTAL RETARDATION | BDNF, MECP2, NTRK2 | GRIA2 43/4885CYP1A2 4876/4885CYP2C19 4863/4885 |
| US-20080194648-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GRM1, GRIN1, HCAR1 | GRIA2 39/4885CYP1A2 980/4885CYP2C19 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.